SalioGen Therapeutics, based in Cambridge, Mass., has developed a Gene Coding platform intended to turn on, turn off, or modify the function of any gene in the genome. The platform is applied through SalioGen’s Exact DNA Integration Technology (EDIT™) and uses mammal-derived genome engineering enzymes called Saliogase™ to integrate new DNA sequences of any length into defined genomic locations without viral vectors. The company positions Gene Coding to address limitations of current gene editing and viral vector–based gene therapies and to broaden the reach of genetic medicines. Management is led by CEO and chairman Ray Tabibiazar, M.D.; Craig Gordon, M.D., founder and CEO of GordonMD Global Investments, joined SalioGen’s board as part of the Series B. Proceeds from the financing are planned to build out the Gene Coding platform, expand the team, establish manufacturing and automation capabilities critical for Gene Coding, and accelerate advancement of preclinical programs. The company completed a $115M Series B financing in 2022. SalioGen Therapeutics is a privately held biotechnology company developing the Exact DNA Integration Technology (EDIT) platform, which is centered on a mammal-derived enzyme called saliogase. EDIT delivers an RNA encoding saliogase together with DNA cargo of any length via lipid nanoparticles to enable precise integration at defined genomic locations without homologous recombination. The company positions the platform as broadly applicable with manufacturing advantages and the potential to enable durable, safe, and affordable non-viral gene therapies. SalioGen’s initial therapeutic focus includes lead programs in familial hypercholesterolemia and inherited macular degeneration, and the company also notes potential applications in cell therapy and biologics manufacturing. The company has assembled a leadership team with experience in gene therapy, medical genetics, lipid nanoparticles, and cell therapy and has strengthened its board of directors and scientific advisory board. SalioGen closed a $20 million Series A to fund preclinical validation of the EDIT platform and its lead programs.

Total raised

$135M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2022